Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

Mark G Lebwohl; Jeffrey L Sugarman; Linda Stein Gold; Tina Lin; Gina Martin

doi:10.25251/skin.3.supp.29

Mark G Lebwohl

Icahn School of Medicine at Mount Sinai, New York, NY

Jeffrey L Sugarman

University of California, San Francisco, CA

Linda Stein Gold

Henry Ford Hospital, Detroit, MI

Tina Lin

Ortho Dermatologics, Bridgewater, NJ

Gina Martin

Bausch Health Americas, Inc, Petaluma, CA

Keywords

psoriasis, tazarotene, halobetasol

Abstract

Abstract not available.

References

1. Nestle FO, et al. N Engl J Med. 2009;361(5):496-509.

2. Cohen SN, et al. Clin Exp Dermatol. 2012;37 Suppl 1:13-18.

3. Menter A, et al. J Am Acad Dermatol. 2009;60(4):643-659.

4. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855-861.

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.29

How to Cite

[1]

Lebwohl, M.G., Sugarman, J.L., Gold, L.S., Lin, T. and Martin, G. 2019. Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S29. DOI:https://doi.org/10.25251/skin.3.supp.29.

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Linda Stein Gold, Joshua Zeichner, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi, DFD 29, a low dose oral minocycline, shows significant improvement in quality of life in subjects with papulopustular rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Brad Glick, Edward Lain, Tina Lin, Robert Israel, Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast) , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Hee J Kim, Mark G Lebwohl, Combination of Calcipotriene Foam, 0.005% and Tazarotene Foam, 0.1% in the Treatment of Plaque Psoriasis of the Scalp and Body: A Case Report , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Andrew F Alexis, Paul S Yamauchi, Tina Lin, Gina Martin, Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Philip J. Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, Andrea Flower, Linda Stein Gold, Dawn Nicewarner, Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet’s Syndrome , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue

<< < 1 2 3 4

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)